Autophagy sits at the center of cancer cell survival and adaptation
Autophagy has shifted from a housekeeping pathway to a central driver of malignant fitness. In cancer, this lysosome-dependent recycling system is not static; it changes with tumor stage, oncogenic wiring, oxygen tension, and nutrient supply. Early in tumorigenesis, autophagy restrains damage by clearing defective organelles, excess reactive oxygen species, and misfolded proteins. Once a tumor is established, the same machinery can be repurposed to sustain growth, preserve mitochondrial function, and help malignant cells endure therapy.
That switch is the biological core of the review. The pathway does not simply rise or fall; it is rewired by oncogenic signaling and by stress in the tumor microenvironment. PI3K/Akt/mTOR signaling suppresses autophagy when anabolic growth is favored, while AMPK and hypoxia-linked programs restore autophagic flux when energy is scarce. The result is a survival program that helps cancer cells weather metabolic collapse, immune pressure, and treatment-induced injury.
Oncogenic signaling rewires the autophagic switch
Several canonical pathways control whether autophagy remains low, becomes blocked, or is reactivated. The PI3K–PDK1–AKT–mTOR axis is the dominant negative regulator. When receptor tyrosine kinases activate PI3K and AKT, mTORC1 suppresses ULK1 and shuts down autophagy initiation. In tumors with PIK3CA gain-of-function, PTEN loss, AKT activation, or MTOR activation, this signaling favors protein synthesis, biomass accumulation, and rapid proliferation.
A second layer of regulation comes from the RAS–RAF–MEK–ERK pathway. Oncogenic KRAS, NRAS, or BRAF signaling can increase dependence on autophagy rather than simply suppressing it. In pancreatic, lung, and melanoma settings, sustained MAPK activity appears to create metabolic stress that cancer cells offset by using autophagy for nutrient recycling and mitochondrial quality control. This is one reason combined MAPK and autophagy inhibition has become a recurring strategy in preclinical cancer research.
AMPK pulls in the opposite direction. As an energy sensor, it responds to falling ATP by activating ULK1 and suppressing mTORC1. In stress-heavy tumors, that response can enable survival rather than destruction. The pathway is protective in normal tissue homeostasis, yet in advanced malignancy it can help cancer cells adapt to scarcity.
Selective autophagy gives tumors more than one escape route
The review places unusual emphasis on selective autophagy rather than only the canonical bulk pathway. Cargo receptors such as p62/SQSTM1 and the KEAP1–NRF2 signaling axis connect autophagy to oxidative stress programs and redox adaptation. Hypoxia-induced mitophagy receptors, including BNIP3, NIX/BNIP3L, and FUNDC1, strip away damaged mitochondria and reduce toxic reactive oxygen species. ER-phagy regulators such as FAM134B and SEC62 help cells clear stressed endoplasmic reticulum and blunt proteostatic injury.
A single sentence captures the clinical logic: damaged organelles are not always liabilities to a tumor; often they are raw material for survival.
These selective systems matter because they are more precise than bulk recycling. A tumor under hypoxia does not merely need more amino acids. It needs to remove dysfunctional mitochondria, avoid apoptosis, preserve membrane integrity, and maintain a manageable level of cellular stress. Selective autophagy delivers exactly that kind of fine control.
Stemness and therapeutic resistance converge on the same pathway
Cancer stem cells are a major reason tumors persist after apparently effective therapy. The review connects autophagy to this stem-like state by describing how recycling pathways support self-renewal, metabolic flexibility, and survival under hostile conditions. Cancer stem cells often require stable mitochondrial fitness and the ability to adapt quickly to fluctuating oxygen and nutrient availability. Autophagy helps maintain both.
This has practical implications for resistance. When chemotherapy, targeted therapy, or radiation imposes stress, autophagy can become a buffer that prevents cell death. Cells that survive that stress may retain stem-like behavior and seed recurrence. In this setting, autophagy is not a passive cleanup mechanism. It becomes part of the resistance architecture.
Immune evasion extends autophagy’s reach beyond the tumor cell
The review also places autophagy inside the tumor microenvironment, where it shapes immune behavior rather than only cancer cell biology. Autophagic flux influences macrophage recruitment and polarization, which in turn alters whether the microenvironment leans toward inflammation or suppression. Secretory autophagy adds another layer by diverting factors such as IL-1β, IL-6, and HMGB1 into the extracellular space instead of lysosomal destruction.
Those secreted molecules can amplify inflammation, stromal remodeling, and pro-migratory signaling. In practical terms, autophagy helps tumors talk to surrounding immune and stromal cells in ways that favor persistence. The pathway can therefore promote immune evasion both inside malignant cells and through the cells that surround them.
Why Beclin 1 and p62 remain central to the field
Two nodes recur across the review: Beclin 1 and p62/SQSTM1. Beclin 1 sits at the start of autophagosome nucleation through the VPS34 complex and is presented as a haploinsufficient tumor suppressor. Monoallelic loss or reduced expression has been described in several cancers, including breast, ovarian, and prostate malignancies. Reduced Beclin 1 weakens quality control and allows damaged cellular material to accumulate, which can promote genomic instability and inflammation.
p62 plays a different role. As a cargo adaptor, it links ubiquitinated material to autophagic degradation, and its involvement in the KEAP1–NRF2 axis ties autophagy to oxidative stress responses. This is one reason the pathway is so difficult to classify as simply “good” or “bad.” The same machinery can restrain early transformation and later help established tumors survive.
Therapeutic targeting remains attractive, but context still governs risk
The most actionable message from the review is not that autophagy should always be blocked. It is that timing, tumor genotype, and disease stage determine whether inhibition will help or harm. In a tumor already dependent on autophagy, blocking the pathway may expose metabolic fragility and amplify treatment response. In earlier disease, broad inhibition could remove a process that normally limits damage and inflammation.
Intervention will likely need to be matched to pathway state rather than applied as a universal rule. Tumors driven by PI3K/Akt/mTOR, RAS/MAPK, or hypoxia-linked mitophagy may not behave the same way, even if all rely on autophagy in some form. The review points toward combination strategies that pair autophagy blockade with targeted therapy or conventional treatment, especially in tumors showing adaptive dependence on recycling pathways.
The unresolved challenge is specificity. Autophagy is deeply integrated into normal tissue homeostasis, immune signaling, and stress adaptation, so any attempt to target it in cancer will need to account for the stage of disease, the dominant oncogenic driver, and the surrounding immune context.